Event Title

Chemoresistant Ovarian Cancer Cells

Session Number

Project ID: MEDH 20

Advisor(s)

Dr. Tong-Chuan He; University of Chicago

Dr. Ling Zhao; University of Chicago

Discipline

Medical and Health Sciences

Start Date

22-4-2020 10:05 AM

End Date

22-4-2020 10:20 AM

Abstract

Randomized 19-nucleotide RNA (N19) library sequences were stably inserted into bone cancer cells and treated with lethal doses of chemotherapy drug nutlin3a. The surviving cells were selected and next-generation DNA sequencing of the nutlin3a resistant cell pool identified highly enriched N19 sequences, which are designated as nutlin3a-resistant transcripts or NRTs. The ability of these NRTs to recapitulate nutlin3a resistance in nutlin3a sensitive human cancer lines were tested. The results show that NRT2, NRT7, NRT10, and NRT15 were found to confer such resistance phenotype. In this study, we tested if NRT2, NRT7, NRT10, or NRT15 in human ovarian cells can confer resistance to paclitaxel. These NRTs were inserted into ovarian cancer cells and treated with varying concentrations of paclitaxel. The results show that NRT15 can confer resistance in ovarian cancer cells.

Share

COinS
 
Apr 22nd, 10:05 AM Apr 22nd, 10:20 AM

Chemoresistant Ovarian Cancer Cells

Randomized 19-nucleotide RNA (N19) library sequences were stably inserted into bone cancer cells and treated with lethal doses of chemotherapy drug nutlin3a. The surviving cells were selected and next-generation DNA sequencing of the nutlin3a resistant cell pool identified highly enriched N19 sequences, which are designated as nutlin3a-resistant transcripts or NRTs. The ability of these NRTs to recapitulate nutlin3a resistance in nutlin3a sensitive human cancer lines were tested. The results show that NRT2, NRT7, NRT10, and NRT15 were found to confer such resistance phenotype. In this study, we tested if NRT2, NRT7, NRT10, or NRT15 in human ovarian cells can confer resistance to paclitaxel. These NRTs were inserted into ovarian cancer cells and treated with varying concentrations of paclitaxel. The results show that NRT15 can confer resistance in ovarian cancer cells.